1 Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore
2 Case scenario Madam TAA is a 5' 3," 100kg 58 yo female She is admitted to have a right total knee replacement. Her past medical history includes hypertension and moderate COPD. No personal and family history of VTE. Her home medications include hydrochlorothiazide 25 mg po daily, spiriva and albuterol. She has stopped smoking 1 year ago.
3 Question 1 1. Which of following is NOT a known risk factor for VTE development for Madam TAA? a. Obesity. b. Hypertension. c. COPD. d. Total knee replacement surgery. e. Age 58 years
4 Question 2 2. What is the minimum amount of time Madam TAA should receive VTE prophylaxis? a. 2 days. b. 3 days. c. 5 days. d. 7 days. e. 10 days.
5 VTE = spectrum of DVT + PE Common clinical problem. Significant morbidity and mortality. Major impact on one s health. Economic burden on healthcare system.
6 VTE - Pathophysiology VTE is a complex (multifactorial) disease, involving interactions between various risk factors. Stasis Alteration in normal blood flow VIRCHOW S TRIAD Endothelial Injury Injury or trauma to the inside of the blood vessel Hypercoagulability Alternation in the constitution of blood causing blood to clot more easily
7 VTE - Incidence Annual incidence of VTE in general population 104 to 183 per 100,000 person-years Males 130 per 100,000 person-years Females 110 per 100,000 person years Arch Intern Med. 1998; 158(6): VTE prophylaxis Identify patients who are at increased risk of VTE.
8 Assessing VTE Risk Who should be assessed? ALL adult patients admitted into hospital Others: Preadmission for elective surgery Patient Groups Patients discharged from ED with significantly reduced mobility relative to normal state eg in a cast/boot following lower leg injury Pregnant and post-partum women
9 Outpatient and Inpatient VTE are Linked 74% of VTEs present in outpatients. 26% of VTEs present in in-patients. 42% of outpatient VTE patients have had recent surgery or hospitalization. Spencer FA, et al. Arch Intern Med 2007; 167:
10 Misunderstandings of VTE prophylaxis Unfortunately, VTE prophylaxis for high risk hospitalized patients is extremely underutilized due to historical misconceptions. 1. the belief that the overall incidence of VTE among hospitalized and postoperative patients is too low to consider prophylaxis; 2. fear of bleeding from anticoagulants; 3.unawareness that prophylaxis is effective at decreasing VTE-associated morbidity and mortality; 4. unawareness that broad application of prophylaxis may be cost-effective; and 5. perceptions that VTE is not a significant problem in their practice. 6. the belief that risk of VTE is limited to in-patient stay and doesn t extend into out-pt setting.
11 Misunderstanding 1. Overall incidence of VTE is too low to consider prophylaxis Incidence of VTE without prophylaxis 10 to 40% of medical or surgical hospitalised patients 40 to 60% following major orthopedic surgery. It has been estimated that 10% of hospital deaths are due to pulmonary embolism. Chest. 2004;126:338S 400S. Therefore, VTE is considered the number one cause of preventable death among hospitalized patients.
13 Misunderstanding 2. Fear of bleeding from anticoagulation Bleeding is viewed as an act of Commission. Development of VTE is not viewed as an act of Omission.
16 Misunderstanding 3. Broad application of VTE prophylaxis is expensive
17 Misunderstanding 3. Broad application of VTE prophylaxis is expensive In a population-based study, adjusted mean predicted costs over 5 years were found to be 2.5-fold higher for patients with VTE related to current or recent hospitalization for acute illness (US$62,838) than for hospitalized control patients ($24,464; P <0.001). Cost differences between cases and controls were greatest ($16,897) within the first 3 months. Am. J. Manag. Care. 2015;21:e255 e263
18 Misunderstanding 3. Broad application of VTE prophylaxis is expensive Similarly, the 5-year costs were predicted to be 1.5-fold higher for patients with VTE related to current or recent hospitalization for major surgery ($55,956) than for hospitalized control patients matched by the type of surgery ($32,718; P <0.001). Cost differences between cases and controls were again greatest ($12,381) in the first 3 months after the index date. Surgery. 2015;157:
19 Misunderstanding 4. VTE is not a significant problem in Asia Singapore studies suggest that VTE risk is increasing in our hospitalised patients % ( ) 0.158% ( ) 0.454% ( )
20 Misunderstanding 5. VTE risk ends upon discharge from hospital VTE can occur for up to 3 months after total knee and hip arthroplasty 1 Hypercoagulability can persist for 4-6 weeks after hip fracture 2 Venous function was significantly impaired for up to 35 days following hip fracture surgery 3 1. White RH et al. Arch Intern Med. 1998;158: Wilson D et al. Injury. 2001;32: Wilson D et al. Injury. 2002;33:33-39.
21 Misunderstanding 6. Unaware that prophylaxis is effective in preventing VTE VTE Prophylaxis in 19,958 Medical Patients/ 9 Studies (Meta-Analysis) 62% reduction in fatal PE 57% reduction in fatal or nonfatal PE 53% reduction in DVT Dentali F, et al. Ann Intern Med 2007; 146:
23 VTE prophylaxis - Conceptual Framework All hospitalized patients must be routinely evaluated for VTE prophylaxis on admission. Patients should be reassessed within 24 hours of admission and whenever the clinical situation changes. All surgical patients, and all medical patients with significantly reduced mobility, should be considered for further risk assessment. VTE pharmacoprophylaxis involves a tradeoff between preventing thrombosis and causing bleeding When making tradeoffs, need to compare absolute risks of thrombosis and bleeding - VTE risk assessment - Bleeding risk assessment
24 VTE risk assessment models No consensus on what is best in clinical practice Individualized point-based scoring (quantitative) models Generally more rigorously validated in determining risk, but not in clinical practice Examples: Caprini Padua IMPROVE Grouping or bucket models Generally not as well validated in predicting risk, but easier to implement, Examples: NICE / NHS guidelines, Australia / New Zealand working group model Classic 3 bucket model Updated 3 bucket grouping model Although there are many tools for assessing thromboembolism risk, there is insufficient evidence to recommend one over the others. 13
25 Padua Prediction Score Padua Prediction Score one of the most validated prediction tool for assessment of VTE risk in medical patients. Score < 4 Low VTE risk, 0.3% risk of developing symptomatic VTE within 90 days. Score > 4 - High VTE risk, 11% risk of developing symptomatic VTE within 90 days. Cannot apply for critically ill patients.
27 Caprini VTE Risk Assessment tool
29 Updated 3 bucket Model More c/w AT9 guidelines
30 Bleeding risk assessment models
31 Pharmacological Prophylaxis Drug Class Unfractionated heparin LMWH Agents Unfractionated heparin Enoxaparin Dalteparin Preferred in patients with renal impairment Most commonly used agents Require dosage adjustment in renal impairment Factor Xa inhibitors Direct thrombin inhibitors Apixaban Rivaroxaban Fondaparinux Dabigatran Alternative for prophylaxis in post- hip or knee replacement Alternative for prophylaxis in post- hip or knee replacement and hip fracture surgery Alternative for prophylaxis in prophylaxis posthip or knee replacement Heparinoid Danaparoid Used in heparin-sensitivity or HIT
32 Pharmacological Prophylaxis Contraindications may include: Contraindications Active bleeding Thrombocytopenia (platelets < 50 x 10 9 /L) End stage liver disease (INR > 1.5) Treatment with therapeutic anticoagulant e.g. warfarin with INR > 2 Severe trauma to head or spinal cord, with haemorrhage in last 4 weeks
33 Mechanical Prophylaxis Devices that increase blood flow velocity in leg veins, reducing venous stasis. Device Graduated Compression Stockings (GCS) Anti-embolic Stocking Intermittent Pneumatic Compression Device (IPC) Foot Impulse Device (FID) Provide graduated compression, which is firmest at the ankle. Used mainly for ambulant patients Standard compression throughout. Used for bedbound or non-ambulant patients Inflatable garment wrapped around legs which is inflated by pneumatic pump. Enhances venous return Stimulates legs veins to mimic walking and reduce stasis. Used for immobilised patients
34 Mechanical Prophylaxis Contraindications may include: Contraindications Skin ulceration Lower leg trauma Morbid obesity (where correct fitting of stocking cannot be achieved) Massive leg oedema or pulmonary oedema due to CCF Stroke patients (avoid compression stockings) Significant PAD cannot use IPCs
36 Case scenario Madam TAA is a 5' 3," 100kg 58 yo female She is admitted to have a right total knee replacement. Her past medical history includes hypertension and moderate COPD. No personal and family history of VTE. Her home medications include hydrochlorothiazide 25 mg po daily, spiriva and albuterol. She has stopped smoking 1 year ago.
37 Question 1 1. Which of following is NOT a known risk factor for VTE development for Madam TAA? a. Obesity. b. Hypertension. c. COPD. d. Total knee replacement surgery. e. Age 58 years
38 Question 1 1. Which of following is NOT a known risk factor for VTE development for Madam TAA? a. Obesity. b. Hypertension. c. COPD. d. Total knee replacement surgery. e. Age 58 years
39 Question 2 2. What is the minimum amount of time Madam TAA should receive VTE prophylaxis? a. 2 days. b. 3 days. c. 5 days. d. 7 days. e. 10 days.
40 Question 2 2. What is the minimum amount of time Madam TAA should receive VTE prophylaxis? a. 2 days. b. 3 days. c. 5 days. d. 7 days. e. 10 days.
41 Conclusions VTE prophylaxis is justified, low-risk, and indicated in most hospitalized patients. Overall, VTE prophylaxis is under-utilized. Physician hesitation is due to misunderstandings. Appropriate prophylaxis should be delivered for an appropriate duration. Each hospital needs a standardized approach for VTE prophylaxis to improve compliance protocols, pre-printed orders, risk stratification, etc. Multi-disciplinary approach auditing
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical
Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH President and CEO Dale W. Bratzler, DO, MPH Oklahoma Foundation for Medical Quality QIOSC Medical Director
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism NICE guideline Published: 21 March 2018 nice.org.uk/guidance/ng89 NICE 2018. All rights
GUIDELINE FOR THROMBOPROPHYLAXIS IN ADULT (18 YEARS AND OLDER) IN GENERAL MEDICAL PATIENTS AND INPATIENTS UNDERGOING SURGERY SEE SEPARATE GUIDELINES FOR THROMBOPROPHYLAXIS IN OBSTETRICS This guidance does
The College of Emergency Medicine Patron: HRH The Princess Royal Churchill House Tel +44 (0)207 404 1999 35 Red Lion Square Fax +44 (0)207 067 1267 London WC1R 4SG www.collemergencymed.ac.uk CLINICAL EFFECTIVENESS
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
Jessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks 1. What is the most common cause of death in hospitalized patients? 1. Hospital-acquired infection 2. Pulmonary embolism 3. Myocardial infarction
Postsurgical Home Use of Limb Compression Devices Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See Also: Postsurgical Home Use of Limb Compression
Guideline Quick View: Venous Thromboembolism The AORN Guideline Quick View is a key component of Guideline Essentials, a suite of online implementation tools designed to help the perioperative team translate
ASH Recommendations for VTE in Non-Surgical Patients INTRODUCTION American Society of Hematology (ASH) guidelines are based on a systematic review of available evidence. Through a structured process, a
Name: Procedure: Doctor: Date: THROMBOSIS RISK FACTOR ASSESSMENT CHOOSE ALL THAT APPLY EACH RISK FACTOR REPRESENTS 1 POINT Age 41 60 years Minor Surgery Planned History of Prior Major Surgery (< 1 month)
2015 Thromboprophylaxis Guidelines for Adult Patients in: Medicine, Haematology & Oncology, Intensive Care Unit, Surgery, Orthopaedics, Major Trauma. Title Thromboprophylaxis guidelines for adult patients
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
June 2012 National Policy Framework: VTE Prevention in Adult Hospitalised Patients in NZ i Editor: Anne Blumgart - Project Manager NZ VTE Prevention Programme / Principal Pharmacist Drug Utilisation Evaluation,
Updates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan Objectives Describe the prevalence of PE and DVT as it relates
Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis
PE and DVT Dr Anzo William Adiga WatsApp or Call +256777363201 Medical Officer/RHEMA MEDICAL GROUP OBJECTIVES DEFINE DVT AND P.E PATHOPHYSIOLOGY OF DVT CLINICAL PRESENTATION OF DVT/PE INVESTIGATE DVT MANAGEMENT
Clinical Practice Guideline for Patients Requiring Total Hip Replacement Inclusions Patients undergoing elective total hip replacement Exclusions Patients with active local or systemic infection or medical
Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center
Title of Guideline THROMBOPROPHYLAXIS IN ORTHOPAEDIC SURGERY Contact Name and Job Title (Author) Gary Masterman Deputy Chief Pharmacist (Governance) Division & Specialty Specialist Services Guideline Number
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
I CSI Health Care Guideline: Venous Thromboembolism Prophylaxis I NSTITUTE FOR CLINICAL S YSTEMS IMPROVEMENT Fourth Edition June/2007 The information contained in this ICSI Health Care Guideline is intended
Alan Banks, DPM Tucker, GA Balancing the risk between the prevention of DVT / PE and increased bleeding. American College of Chest Physicians 2012 Chest We suggest no prophylaxis in patients with isolated
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-60 Effective Date: 05/19/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
SH CP 50 Venous Thromboprophylaxis Policy Version 3 Summary: Policy for the management and prevention of venous thrombosis for patients whilst in the care of Southern Health NHS Foundation Trust. Keywords
Edoxaban for treating and for preventingenting deep vein thrombosis and pulmonary embolism Technology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta354 NICE 2017. All rights reserved.
NEW NICE guidance NICE guidance (MTG19) supports the use of the geko device for people who have a high risk of VTE and for whom pharmacological or other mechanical methods of VTE prevention are impractical
Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with
NICE guidance NICE guidance (MTG19) supports the use of the geko device for people who have a high risk of VTE and for whom pharmacological or other mechanical methods of VTE prevention are impractical
ARTEMIS ARixtra (fondaparinux) for ThromboEmbolism prevention in NV Organon Protocol 63129 a Medical Indications Study Objective To demonstrate efficacy and to assess safety of oncedaily subcutaneous (SC)
Management of Venous Disease: an evidence based approach Disclosures Ed Boyle, MD Andrew Jones, MD Dr. Ed Boyle and Dr. Andrew Jones disclose Grants/research support: Medtronic, BTG International, Clearflow,
MANAGEMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS (DVT) IN THE COMMUNITY SETTING & ANTICOAGULATION CLINICS THE PAST, PRESENT AND THE FUTURE Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance
Prevention and management of venous thromboembolism M. AAPRO Thromboprophylaxisof DVT and PE in AmbulatoryCancerPatients Zurich, February 2017 M. AAPRO Based on a lesson in April 2016 by M. DICATO M.D.,
Dear Thank you for your Freedom of Information request concerning compliance of Trust's VTE prevention policies with national VTE prevention best practice. The Trust can provide the following information:
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
Pulmonary Thromboembolism James Allen, MD Epidemiology of Pulmonary Embolism 1,500,000 new cases per year in the United States Often asymptomatic 300,000 deaths per year DVT or PE present in 10% of ICU
Management of Cancer Associated Thrombosis (CAT) where data is lacking Tim Nokes Haematologist, Derriford Hospital, Plymouth Contents Overview of the statistics and aetiology for Cancer Associated Thrombosis
» Walk Away From Risk Mimic ambulation to prevent DVT Walk Away From Risk VenaFlow Elite s unique technology is proven to mimic ambulation and reduce DVT to help healthcare facilities and patients walk
Issue date: April 2007 Venous thromboembolism Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery) NICE clinical guideline 46 Developed
ADULT VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS GUIDELINE This document is intended as a guideline only and should not replace sound clinical judgment. I. VTE risk assessment and selection of prophylaxis:
ACCP CLINICAL RESOURCE Facilitating Learning and Change in Clinical Care Antithrombotic Therapy and Prevention of Thrombosis 9th Edition: American College of Chest Physicians Evidence-Based Clinical Practice
THROMBOEMBOLIC DISEASE: THE WHY S AND HOW S Jonaki Manna, MD, FRCPC Hematopathology OVERVIEW 1. Normal thrombosis 2. Classification of all thrombotic diseases D V T / P E 3. Definitions and Epidemiology
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
Asian Pacific Journal of Tropical Disease (2012)S707-S711 707 Contents lists available at ScienceDirect Asian Pacific Journal of Tropical Disease journal homepage:www.elsevier.com/locate/apjtd Document
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/2 (CIP: 34009 359 225 4 0) B/7 (CIP:
Company Introduction We are the leading company of various pneumatic medical systems since 1986. We are exporting our products to 60 countries. We provide the products with high quality and competitive
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
Document Control Title Use and monitoring of Low Molecular Weight Heparins (LMWHs) in community hospitals and community nursing Clinical Guidelines Author Team Directorate Medical Date Version Status Issued
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
Patterns of Failure of a Standardized Perioperative Venous Thromboembolism Prophylaxis Protocol Ryan Macht MD, Michael Cassidy MD, Pamela Rosenkranz RN BSN MEd, Joseph Caprini MD FACS, David McAneny MD
Heparin-Induced Thrombocytopenia (HIT) Joshua Ononuju, Pharm. D. Owensboro Medical Health Systems Objectives Overview Pathogenesis Risk factors Clinical Presentation and Diagnosis Treatment goals and options
Running Head: BEST PRACTICE FOR DEEP VEIN THOMBOSIS PREVENTION 1 Best Practice for Deep Vein Thrombosis Prevention: A Research Review Pamela Dusseau Carly Macklin Natalie Russell Danielle Williams Ferris
Page 1 of 11 Venous Thromboembolism () What is a clot or Venous Thromboembolism ()? Blood clots are called Venous Thromboembolism (). There are 2 main types: is a clot in a deep vein, usually an arm or
ΘΡΟΜΒΟΔΜΒΟΛΙΚΑ ΔΠΔΙΟΓΙΑ ΣΗ ΜΔΘ ΓΙΑΝΝΗ ΚΑΨΟΚΑΛΤΒΑ ΔΙΓΙΚΔΤΟΜΔΝΟ ΑΝΑΙΘΗΙΟΛΟΓΙΑ Α.Ν.Θ. ΘΔΑΓΔΝΔΙΟ Virchow's triad. Kyrle P A, Eichinger S Blood 2009;114:1138-1139 2009 by American Society of Hematology Biomaterials
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
Inferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski Department of Surgery Grand Rounds March 24, 2008 History of Vena Cava Filters Virchow-1846-Proposes PE originate from veins
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email email@example.com Overview Highlights of the 4 new approved oral anticoagulants Results from
Acute and long-term treatment of VTE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE The goals The acute PE phase After the acute phase Treatment for VTE Goals of acute treatment
GUIDELINES European guidelines on perioperative venous thromboembolism prophylaxis Day surgery and fast-track surgery Linas Venclauskas, Juan V. Llau, Jean-Yves Jenny, Per Kjaersgaard-Andersen and Øivind
CHEST Supplement ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES Prevention of VTE in Orthopedic Surgery Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:
Apixaban for the treatment and secondary prevention ention of deep vein thrombosis and/or pulmonary embolism Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta341 NICE 2017. All
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations